Clinical trial
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid…
NCT00131989 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00131989 |
|---|---|
| Title | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
| Official title | Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15 and 12 more |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, pharmacological study, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2007 |
| First posted | Aug 19, 2005 |
| Last update posted | Jan 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: